Elanco's Long-Acting Transdermal Buprenorphine for Cats Gains FDA Approval

The FDA has approved Elanco Animal Health Inc ELAN Zorbium (buprenorphine transdermal solution) to control postoperative pain associated with surgical procedures in cats.

• The approval expands Elanco's pain management offerings for veterinary practices.
• Zorbium provides up to four days of pain control from a single transdermal dose without relying upon owners to administer an opioid after discharge and the need for repeat injections.
• Related: Elanco To Lay Off 20% Senior Management In Organizational Restructure. 
• Consistent pain control reassures cat owners and reduces the challenges of administering pain medications at home.
• Zorbium is for topical application in cats only. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site.
• Related content: Benzinga's Full FDA Calendar.
• Price Action: ELAN shares closed at $26.83 on Thursday.